Poster Session 1 - Friday, August 26, 2016

LOCATION: EXHIBIT HALL
PRESENTING AUTHOR STAND BY TIME: 10:30 - 11:00 AND 16:00 - 16:30

PREVENTION, EARLY DETECTION, EPIDEMIOLOGY AND TOBACCO CONTROL

P1.01 Herbal Medicine Today: Clinical and Research Issues
TAQEE ANSARI Mohammed, IN

P1.02 Lung Cancer - a Previously Years Survival Study. First Statistical Evidence at National Institute of Oncology in Paraguay
Silvia Ayala Leon, PY

P1.03 Utility of a Combined Panel of Six Serum Tumor Markers for Lung Cancer
Rafael Molina, ES

P1.04 Defining the Genetic Architecture of Lung Cancer Etiology
Christopher Amos, US

P1.05 An International Epidemiological Analysis of Young Patients Diagnosed with NSCLC (AduJoV-CLiCaP)
Luis Corrales-Rodriguez, CR

P1.06 Lung Nodule Volumetry: Analysis of the Measurement Variation
Wilson Ezequiel Neto, BR

P1.07 University Students’ Perceptions about Effectiveness of MPOWER Policies on Tobacco Control
Omar Castillo-Fernandez, PA

P1.08 Updated Analysis of Global Epidemiology of EGFR Mutation in Advanced Non-Small Cell Lung Cancer
Gilberto Lopes, BR

P1.09 Delays in the Diagnosis and Treatment of Lung Cancer
Martin Richardet, AR

P1.10 Follow-Up on Results of a Multidisciplinary Team in the Management of Non-Small Cell Lung Cancer in a Developing Country
Luis Corrales-Rodriguez, CR

P1.11 Surveillance System of Tabaqism in Cuba 1995-2014 and Early Detection in Heavy Smokers
Patricia Varona Perez, CU

P1.12 (also presented as PD1.03) EGFR Mutation Testing Patterns and Results in Brazil and the Need for Greater Public Health Awareness of Molecular Testing
Gilberto Lopes, BR

P1.13 (also presented as PD2.01) Gene Expression Profiles of Hispanics Living in the US or Latin America Are Similar
Luis Raez, US

P1.14 Energy-Based Instruments for Pulmonary Artery Ligation in Thoracoscopic Major Lung Resection
Yoshio Tsunezuka, JP

EARLY STAGE NSCLC (STAGE I - III)

P1.15 Comparison of Pulmonary Function after Robotic-Assisted Video-Thoracoscopic Lobectomies vs Segmentectomies
Eric Toloza, US

P1.16 Comparison of Peri-Operative Outcomes after Robotic-Assisted Video-Thoracoscopic Lobectomies versus Segmentectomies
Eric Toloza, US
# Improved Survival for Stage-2 (N1) Pulmonary Adenocarcinoma and Squamous Cell Carcinoma after Pulmonary Lobectomy
Danny Nguyen, US

# Long-Term Clinical Outcomes and Safety Profile for Central Lung SBRT for NSCLC
Kenneth Merrell, US

# Barriers to Deliver Personalized Medicine to Young Patients with Non-Small Cell Lung Cancer in Latin America
Liliana Fernandez, CO

# Lung Resection Analysis from Brazilian Society of Thoracic Surgery Database
Maria Teresa Ruiz Tsukazan, BR

# Novel PET Parameters as Predictors of Pathologic Response in Patients with Stage II (T3N0M0) Lung Adenocarcinoma after Pulmonary Lobectomy
Andrea Arnett, US

# Temporal Survival Improvement for Stage-II (T3N0M0) Lung Adenocarcinoma after Pulmonary Lobectomy
Danny Nguyen, US

# Overall Survival In Patients with Metastatic Lung Adenocarcinoma Treated at Instituto Oncologico Nacional. Panama
Mario Guardia, PA

# "Real World" Use of Liquid Biopsy in Patients with Lung Adenocarcinoma and Correlation with Tumor Tissue Genetic Profile
Edgardo Santos, US

# Clinical Efficacy and Tolerability of Bevacizumab in Elderly Patients With Advanced Non-Squamous NSCLC.
Lilibeth Castillero, PA

# Pleural Empyema and Broncho Pleural Fistula after Lung Resection: Analyses of 29 Patients Treated in Our Clinic
Fadil Gradica, AL

# Primary Lung Cancer Presenting as Pneumothorax
Fadil Gradica, AL

# Afatinib versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6
Luis Fein, AR

# First-Line Afatinib vs Gefitinib for Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial
Santiago Ponce Aix, ES

---

**Friday, August 26, 2016**

**ADVANCED NSCLC**

# Chemotherapy in Lung Cancer at National Institute of Oncology at Paraguay: A Retrospective Study, 8 Years of Experience
Silvia Ayala Leon, PY

# 1st Line Treatment with Erlotinib in Advanced Non Squamous NSCLC: Our Experience. CCSS, San José Costa Rica
Raquel Rojas-Vigott, CR

# Experience with Erlotinib and Gefitinib in Patients with EGFR Mutation Positive Advanced Lung Cancer
Cristiane Martin, PA

---

**IASLC 7TH LATIN AMERICAN CONFERENCE ON LUNG CANCER**

August 25-27, 2016 • Panama City, Panama

WWW.IASLC.ORG
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.35</td>
<td>The Role of Salvage SBRT in Recurrent Lung Cancer after Previous Radiotherapy</td>
<td>Beatriz Amendola</td>
<td>US</td>
</tr>
<tr>
<td>P1.36</td>
<td>Non-Small-Cell Lung Cancer and Brain Metastases in Brazil</td>
<td>Luiza Weis</td>
<td>BR</td>
</tr>
<tr>
<td>P1.37</td>
<td>First Line Treatment Outcome for EGFR Mutated Metastatic Non-Small Cell Lung Cancer-A Single Institution 5 Years Experience</td>
<td>Shahid Gilani</td>
<td>GB</td>
</tr>
<tr>
<td>P1.38</td>
<td>Relationship Between TILs and Neutrophil-Lymphocyte Ratio As A Prognostic Factor In Advanced NSCLC</td>
<td>Martin Richardet</td>
<td>AR</td>
</tr>
<tr>
<td>P1.39</td>
<td>Only Two Rare Metastasis of Lung Adenocarcinoma?</td>
<td>Cláudia Matos</td>
<td>PT</td>
</tr>
<tr>
<td>P1.40</td>
<td>Comparative Study of Chemotherapy Regimens Based on Platinum and Its Different Toxicities in Patients with Advanced NSCLC</td>
<td>Martin Richardet</td>
<td>AR</td>
</tr>
<tr>
<td>P1.41</td>
<td>(also presented as PD2.06) Bayesian Network Meta-Comparison of Maintenance Treatments for Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients</td>
<td>Gilberto Lopes</td>
<td>BR</td>
</tr>
<tr>
<td>P1.42</td>
<td>(also presented as PD2.04) Pem/CBP/Bev Followed by Maintenance Pem/Bev in Hispanic Patients with NSCLC: Outcomes According to TS, ERCC1 and VEGF</td>
<td>Leonardo Rojas</td>
<td>CO</td>
</tr>
<tr>
<td>P1.43</td>
<td>(also presented as PD2.05) Radiosurgery, a New Paradigm in Metastatic Non-Small Cell Lung Cancer (NSCLC) to the Brain: An Update</td>
<td>Beatriz Amendola</td>
<td>US</td>
</tr>
<tr>
<td>P1.44</td>
<td>(also presented as PD2.02) Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients with ALK+ NSCLC</td>
<td>Ticiani Leal</td>
<td>US</td>
</tr>
<tr>
<td>P1.45</td>
<td>(also presented as PD2.03) Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6</td>
<td>Carlos Barrios</td>
<td>BR</td>
</tr>
<tr>
<td>P1.46</td>
<td>Phase I Study of Nivolumab + nab-Paclitaxel in Solid Tumors: Preliminary Analysis of the Non-Small Cell Lung Cancer Cohort</td>
<td>Nataliya Trunova</td>
<td>US</td>
</tr>
<tr>
<td>P1.47</td>
<td>ABOUND.sqm QoL by Response: Interim Analysis of Squamous NSCLC Pts Treated with nab-Paclitaxel/Carboplatin Induction Therapy</td>
<td>Nataliya Trunova</td>
<td>US</td>
</tr>
<tr>
<td>P1.48</td>
<td>nab-Paclitaxel + Carboplatin in Advanced Non-Small Cell Lung Cancer: Outcomes in Elderly Patients with Squamous Histology</td>
<td>Teng Jin Ong</td>
<td>US</td>
</tr>
<tr>
<td>P1.49</td>
<td>(also presented as PD1.05) The Genomics of Young Emergent Lung Cancer</td>
<td>Barbara Gitlitz</td>
<td>US</td>
</tr>
<tr>
<td></td>
<td><strong>SUPPORTIVE CARE AND OTHERS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P1.50</td>
<td>Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects with Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy</td>
<td>Carlos Barrios</td>
</tr>
<tr>
<td></td>
<td>P1.51</td>
<td>Impact of Regulatory Delays in Drug Approval: Mortality and Morbidity Due to with Lack of Access to Crizotinib in Brazil</td>
<td>Carlos Barrios</td>
</tr>
</tbody>
</table>

Friday, August 26, 2016